Biomarin Pharmaceutical Inc

NASDAQ: BMRN
$65.99
-$0.05 (-0.1%)
Real Time Data Delayed 15 Min.

BMRN Articles

Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Wednesday's top analyst calls include AMD, Amazon.com, Celgene, Comerica, Fortinet, Gilead Sciences, Lennar, Netflix, Voya and Wayfair.
Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.
24/7 Wall St. has collected four companies big FDA decisions coming up in the first quarter of 2016 and added some color.
A new Jefferies research report focuses on some biotech and specialty pharmaceutical stocks that have had some headline and clinical issues muddy the waters.
Wednesday's top analyst upgrades, downgrades and initiations include Apple, Bluebird, Exxon Mobil, Kinder Morgan, Kinross Gold, Lending Club and Perrigo.
This week the Jefferies analysts are positive on companies that took a shot price-wise last week and may be offering an even better entry point for investors.
24/7 Wall St. tracked 15 fresh analyst calls in this past week alone in which analysts were calling for upside of almost 50% or more.
Friday's top analyst upgrades, downgrades and initiations include Abbott Labs, BioMarin Pharmaceutical, CBS, Cisco, GameStop, Petrobras, Sirius XM, SunPower and Yelp.
These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
A report on Wednesday from Janney Capital Markets has targeted several iotech bcompanies it believes are now grossly oversold.
In a recent research report, Jefferies highlighted three top biotech companies that are very tempting buys now.
Now is the time to really review portfolios and replace momentum winners with earnings growth leaders. The Cowen Focus Call stocks are just the ticket.
SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving clinical and FDA catalysts during the remainder of 2015.
A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.